RETRACTED ARTICLE: Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis

Rui Han(Anhui Medical University), Lizhu Lin(Guangzhou University of Chinese Medicine)

Scientific Reports

April 21, 2021

10.1038/s41598-021-88133-7

Cited by 42

Related Papers

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

|The Lancet Respiratory Medicine|2020|504

Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway

|Phytotherapy Research|2019|64

Negative association of C-reactive protein-albumin-lymphocyte index (CALLY index) with all-cause and cause-specific mortality in patients with cancer: results from NHANES 1999–2018

|BMC Cancer|2024|45

Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer

|Medical Oncology|2022|30

Expert consensus on treatment for stage III non‐small cell lung cancer

|Medicine Advances|2023|18